Summary
Eli Lilly & Company (LLY) filed a Form 8-K on March 12, 2003, primarily to incorporate financial information for an upcoming offering of up to $500 million in fixed-rate notes. This filing serves to furnish investors with essential financial data as part of the prospectus and prospectus supplement to be filed with the SEC. The report includes the company's audited consolidated financial statements, management's discussion and analysis of financial condition and results of operations, and a statement regarding the computation of the ratio of earnings from continuing operations to fixed charges.
Key Highlights
- 1Company intends to file a prospectus and prospectus supplement related to an offering of up to $500 million of fixed-rate notes.
- 2The 8-K filing incorporates financial statements and other information for reference in the upcoming prospectus.
- 3Included exhibits consist of the Statement Regarding Computation of Ratio of Earnings From Continuing Operations to Fixed Charges.
- 4Consent of Independent Auditors is provided as an exhibit.
- 5Exhibit 99.1 contains Management's Discussion and Analysis of Financial Condition and Results of Operations, along with Audited Consolidated Financial Statements.